1. Home
  2. ZNTL vs SVCO Comparison

ZNTL vs SVCO Comparison

Compare ZNTL & SVCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZNTL
  • SVCO
  • Stock Information
  • Founded
  • ZNTL 2014
  • SVCO 1984
  • Country
  • ZNTL United States
  • SVCO United States
  • Employees
  • ZNTL N/A
  • SVCO N/A
  • Industry
  • ZNTL Biotechnology: Pharmaceutical Preparations
  • SVCO
  • Sector
  • ZNTL Health Care
  • SVCO
  • Exchange
  • ZNTL Nasdaq
  • SVCO NYSE
  • Market Cap
  • ZNTL 227.0M
  • SVCO 221.9M
  • IPO Year
  • ZNTL 2020
  • SVCO 2024
  • Fundamental
  • Price
  • ZNTL $3.00
  • SVCO $7.87
  • Analyst Decision
  • ZNTL Buy
  • SVCO Strong Buy
  • Analyst Count
  • ZNTL 8
  • SVCO 6
  • Target Price
  • ZNTL $10.50
  • SVCO $20.83
  • AVG Volume (30 Days)
  • ZNTL 1.1M
  • SVCO 241.5K
  • Earning Date
  • ZNTL 11-12-2024
  • SVCO 02-14-2025
  • Dividend Yield
  • ZNTL N/A
  • SVCO N/A
  • EPS Growth
  • ZNTL N/A
  • SVCO N/A
  • EPS
  • ZNTL N/A
  • SVCO N/A
  • Revenue
  • ZNTL $40,560,000.00
  • SVCO $54,307,000.00
  • Revenue This Year
  • ZNTL N/A
  • SVCO $15.49
  • Revenue Next Year
  • ZNTL N/A
  • SVCO $17.07
  • P/E Ratio
  • ZNTL N/A
  • SVCO N/A
  • Revenue Growth
  • ZNTL N/A
  • SVCO 5.33
  • 52 Week Low
  • ZNTL $2.66
  • SVCO $6.14
  • 52 Week High
  • ZNTL $18.07
  • SVCO $21.59
  • Technical
  • Relative Strength Index (RSI)
  • ZNTL 41.60
  • SVCO N/A
  • Support Level
  • ZNTL $2.80
  • SVCO N/A
  • Resistance Level
  • ZNTL $4.00
  • SVCO N/A
  • Average True Range (ATR)
  • ZNTL 0.27
  • SVCO 0.00
  • MACD
  • ZNTL -0.06
  • SVCO 0.00
  • Stochastic Oscillator
  • ZNTL 17.01
  • SVCO 0.00

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

About SVCO SILVACO GROUP INC

Silvaco Group Inc is a provider of technology computer aided design ("TCAD") software, electronic data automation ("EDA") software and semiconductor intellectual property ("SIP"). TCAD, EDA and SIP solutions enable semiconductor and photonics companies to increase productivity, accelerate their products' time-to-market and reduce their development and manufacturing costs. It is developing the "technology behind the chip" and providing solutions that span from atoms to systems, starting with providing software for the atomic level simulation of semiconductor and photonics material for devices, to providing software and SIP for the design and analysis of circuits and system level solutions.

Share on Social Networks: